ERBB2 and cancer: Gene expression profiling studies on pre- and post-treatment samples of neoadjuvant anti-HER2 study CALGB-40601 showed that HER2 enriched cancers had a higher pCR rate than other types (70% for HER2 enriched vs. 36% for luminal B vs. 34% for luminal A) (53).